Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · IEX Real-Time Price · USD
1.500
+0.010 (0.67%)
Mar 28, 2024, 12:30 PM EDT - Market open

Artelo Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014
Selling, General & Admin
4.235.964.62.770.950.510.11000
Research & Development
5.74.322.841.921.091.250000
Other Operating Expenses
00001.170.590.120.030.010.01
Operating Expenses
9.9310.297.444.693.212.340.230.030.020.02
Operating Income
-9.93-10.29-7.44-4.69-3.21-2.34-0.23-0.03-0.02-0.02
Interest Expense / Income
00.0100000000
Other Expense / Income
-0.64-0.21-0-0.03-1.04-----
Pretax Income
-9.29-10.08-7.44-4.66-2.17-2.34-0.23-0.03-0.02-0.02
Net Income
-9.29-10.08-7.44-4.66-2.17-2.34-0.23-0.03-0.02-0.02
Shares Outstanding (Basic)
3310000000
Shares Outstanding (Diluted)
3310000000
Shares Change
4.48%127.55%403.69%70.67%70.05%-12.22%14.30%19.25%108.41%-
EPS (Basic)
-3.14-3.56-5.97-18.90-15.00-27.60-2.70---
EPS (Diluted)
-3.14-3.56-5.97-18.90-15.00-27.60-2.70---
Free Cash Flow
-8.21-8.01-6.14-4.35-2.79-1.61-0.22-0.02-0.01-0.02
Free Cash Flow Per Share
-2.77-2.83-4.93-17.59-19.29-18.91-2.23-0.22-0.19-0.45
EBITDA
-9.25-10.04-7.43-4.66-2.17-2.34-0.23-0.03-0.02-0.02
Depreciation & Amortization
0.040.040.010000000
EBIT
-9.29-10.08-7.44-4.66-2.17-2.34-0.23-0.03-0.02-0.02
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).